Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
- 1 December 2009
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 4 (12), 1537-1543
- https://doi.org/10.1097/jto.0b013e3181c0a2f4
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLJournal of Clinical Oncology, 2009
- Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2Journal of Clinical Oncology, 2008
- Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2007
- Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancerAnnals of Oncology, 2006
- Albumin-Bound PaclitaxelDrugs, 2006
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- SPARC Inhibits Epithelial Cell Proliferation in Part through Stimulation of the Transforming Growth Factor-β–Signaling SystemMolecular Biology of the Cell, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000